LivingGLP1
Study S002551

Identifying Barriers to and optiMizing In-hosPitaL usE of Evidenced-based Medical thErapies for patieNTs With Cardio-Renal-Metabolic Disease

ClinicalTrials.gov record

Registration

Registration
NCT05781334
Acronym
IMPLEMENT-CRM
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Status
COMPLETED
Enrollment
202
Start
2023-06-09
Primary completion
2024-08-31
Lead sponsor
Duke University
Conditions
Heart Failure; Type 2 Diabetes; Chronic Kidney Diseases
Interventions
OTHER:Virtual Consult Intervention
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors) [hospital discharge (up to approximately 14 days)]
  • Proportion of patients prescribed SGLT2i (sodium glucose co-transporter-2 inhibitors) [30 days post-discharge (approximately 6 weeks)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.